Double blind trial of bezafibrate in familial hypercholesterolaemia.
Kathryn Wheeler(St George's, University of London), R. West(St George's, University of London), J. K. Lloyd(St George's, University of London), J. Barley(St George's, University of London)
Cited by 90Open Access
Abstract
A six month, double blind, crossover controlled trial of bezafibrate was conducted in 14 children with familial hypercholesterolaemia all of whom had a strong family history of early coronary heart disease. The bezafibrate was given twice daily in a dose of 10 to 20 mg/kg/day. The mean plasma total cholesterol concentration on bezafibrate was 22% lower than during the period on placebo and there was a moderate rise in high density lipoprotein cholesterol. Bezafibrate may be a useful adjunct to treatment in these children.